

Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1*H*-indole-3-carboxaldehyde (oncrasin-1)

Wei Guo,¹ Shuhong Wu,¹ Li Wang,¹ Rui-yu Wang,² Xiaoli Wei,¹ Jinsong Liu,³ and Bingliang Fang¹

Departments of ¹Thoracic and Cardiovascular Surgery, ²Stem Cell Transplantation and Cellular Therapy, and ³Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Abstract

Protein kinase C ι (PKC ι) is activated by oncogenic Ras proteins and is required for K-Ras–induced transformation and colonic carcinogenesis *in vivo*. However, the role of PKC ι in signal transduction and oncogenesis is not clear. We recently identified a small molecule, designated 1-[(4-chlorophenyl)methyl]-1*H*-indole-3-carboxaldehyde (oncrasin-1), that can selectively kill K-Ras mutant cancer cells and induce abnormal nuclear aggregation of PKC ι in sensitive cells but not in resistant cells. To determine the causes and biological consequences of PKC ι aggregates in the nucleus, we analyzed the effect of oncrasin-1 on proteins involved in DNA repair and RNA processing. Our results showed that oncrasin-1 treatment led to coaggregation of PKC ι and splicing factors into megaspliceosomes but had no obvious effects on the DNA repair molecule Rad51. Moreover, oncrasin-1 treatment suppressed the phosphorylation of the largest subunit of RNA polymerase II and the expression of intronless reporter genes in sensitive cells but not in resistant cells, suggesting that suppression of RNA transcription is a major effect of oncrasin-1 treatment. Studies with cultured cells or with recombinant proteins showed that oncrasin-1 can disrupt the interaction of PKC ι and cyclin-dependent protein kinase 9/cyclin T1 complex, which is known to phosphorylate the largest subunit of RNA polymerase II and is required for RNA transcription. Together, our results suggest that oncrasin-1 suppresses

the function of RNA processing machinery and that PKC ι might be involved in the biological function of RNA processing complexes. [Mol Cancer Ther 2009;8(2):441–8]

Introduction

Protein kinase C (PKC) is a family of serine/threonine kinases that are activated by many extracellular signals, including hormonal, neuronal, and growth factor stimuli (1). At least 10 known isoforms have been identified and these are classified into three groups on the basis of their structure and activation signaling: (a) conventional PKCs (α , β 1, β 2, and γ), which are activated by phosphatidylserine and diacylglycerol and are Ca²⁺ dependent; (b) novel PKCs (δ , ϵ , η , and θ), which are activated by phosphatidylserine and diacylglycerol but are Ca²⁺ independent; and (c) atypical PKCs (ζ and ι/λ), which are not regulated by phosphatidylserine, diacylglycerol, or Ca²⁺ but are activated by 3-phosphoinositides, phosphoinositide-dependent kinase 1, and specific protein-protein interactions, including direct interaction with Ras protein (2). Phosphorylation of atypical PKCs at Thr⁴¹⁰ (Thr⁴⁰³) by phosphoinositide-dependent kinase 1 is phosphoinositide 3-kinase dependent and serves as a direct on/off switch (3).

Evidence shows that atypical PKCs play roles in signal transduction, cell proliferation, cell polarity, inflammation, and oncogenesis. Increased expression of PKC ζ was observed in pancreatic cancer stromal cells and liver and prostate cancer tissues (4). Similarly, gene amplification and overexpression of PKC ι was reported in human ovarian cancer and non-small cell lung carcinoma (5, 6) and this increased expression was associated with poor survival. Moreover, PKC ι is required for K-Ras–induced transformation and colonic carcinogenesis *in vivo*, suggesting that it is a critical downstream effector of oncogenic Ras (7). Transgenic mice expressing constitutively active PKC ι in the colon are highly susceptible to carcinogen-induced colon carcinogenesis, whereas mice expressing kinase-deficient PKC ι are resistant to both carcinogenic and oncogenic Ras-mediated carcinogenesis (7). Nevertheless, like in other PKC isoforms, the downstream signaling effectors of atypical PKC are not well characterized, although direct interaction between atypical PKC and Phox-Bem1 domain proteins (8), such as Zip/62, Par6, and mitogen-activated protein kinase 5, has been reported (9–11). In addition, nucleolin, a major constituent of nucleoli in exponentially growing cells, has been identified as a substrate of PKC ζ (12). However, evidence also suggests functional divergence between

Received 9/3/08; revised 11/7/08; accepted 11/24/08; published OnlineFirst 02/10/2009.

Grant support: National Cancer Institute grant R01 CA092487 (B. Fang), Lockton grant-matching funds, and Cancer Center Support Grant CA116672.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Bingliang Fang, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030. Phone: 713-563-9147; Fax: 713-794-4901. E-mail: bfang@mdanderson.org

Copyright © 2009 American Association for Cancer Research.

doi:10.1158/1535-7163.MCT-08-0839

442 Interruption of RNA Processing Machinery by Oncrasin-1




Figure 1. Effects of oncrasin-1 on PKC ι , SC35, and Rad51. **A**, aggregation of PKC ι in the nucleus of T29Kt1 cells 12 h after 10 μ mol/L oncrasin-1 treatment. **B**, immunofluorescent staining of PKC ι , SC35, and RAD51. T29Kt1 cells were treated with DMSO, 10 μ mol/L oncrasin-1, or 10-Gy γ -irradiation for 12 h, and immunofluorescent staining was done to determine the intracellular localization of PKC ι , SC35, and Rad51. Treatment with oncrasin-1 induced dramatic morphologic changes in PKC ι and SC35 but not in Rad51. In contrast, no obvious changes were observed in PKC ι and SC35 after radiation treatment.

PKC ι and PKC ζ . Mice with knockout of PKC ζ are viable but have impaired nuclear factor- κ B signaling and immune response (13), whereas mice with knockout of PKC λ , a mouse homologue of PKC ι , do not survive past the embryonic stage (14).

We have recently identified a small molecule, 1-[(4-chlorophenyl)methyl]-1*H*-indole-3-carboxaldehyde (oncrasin-1), that can selectively kill K-Ras mutant cancer cells but has little effect on normal isogenic cells (15). Oncrasin-1 treatment resulted in aggregation of PKC ι in the nucleus in sensitive cells but not in resistant cells. However, the causes and/or biological consequences of PKC ι aggregation inside the nucleus are not clear; therefore, we tested the effect of oncrasin-1 on nuclear proteins involved in the processing of DNA or RNA, the two major molecules that are synthesized, repaired, or processed inside the nucleus. Oncrasin-1 treatment resulted in aggregation of RNA splicing factors in a similar pattern as that observed in PKC ι but had no obvious effects on the DNA repair molecule Rad51. Moreover, oncrasin-1 treatment resulted in the aggregation of PKC ι into megaspliceosomes and reduced phosphorylation of the largest subunit of RNA polymerase II and splicing factors. Thus, our results suggest that oncrasin-1 induces malfunction in the RNA

processing machinery and that PKC ι might be involved in the biological function of RNA processing complexes.

Materials and Methods

Cell Lines

Human non-small cell lung carcinoma H460 cells were propagated routinely in a monolayer culture in RPMI 1640 supplemented with 10% heat-inactivated FCS, 100 units/mL penicillin, and 100 mg/mL streptomycin. T29 and T29Kt1 cells were maintained in DMEM with the same supplements. All cells were maintained in the presence of 5% CO $_2$ at 37°C.

Chemicals and Antibodies

Oncrasin-1 was obtained from Chembridge Corporation. Active CDK9/cyclin T1, CDK7/cyclin H/MAT1, CDK2/cyclin A, CDK6/cyclin D3, histone H1, and CDK7/9 tide were purchased from Millipore. Recombinant PKC ι were purchased from Calbiochem. Antibodies to the following proteins were used for Western blot analysis: PKC ι , alternative splicing factor/splicing factor 2 (ASF/SF2), and Rad51 (Santa Cruz Biotechnology); β -actin (Sigma); antiphosphorylated SR proteins (Invitrogen); AKT, phosphatidylinositol 3-kinase, and phosphor-AKT (Cell Signaling); and purified mouse anti-SC35 (BD Pharmingen), H5 antibody (Covance) and cyclin T1 (Abcam). A 1:1,000 dilution was used for the Western blot analysis and a 1:200 dilution was applied to immunofluorescent slides. The specificity of PKC ι antibody was verified by testing on Western blot analysis of 293 cells transfected with a control plasmid (pCMV-LacZ) or a PKC ι -expressing plasmid pCMV-PKC ι (Supplementary Fig. S1).⁴

Immunofluorescent Staining

Cells were seeded at a density of 1×10^5 per well in six-well plates. Each well contained a 1% gelatin-treated coverslide. Cells were allowed to grow overnight; they were then treated with different compounds or radiation, as indicated in the legends. After treatment, cells were washed twice with PBS, fixed with 2% paraformaldehyde for 20 min, permeabilized with 0.1% Triton-100 for 20 min, and blocked with 5% normal goat serum for 1 h. The slides were incubated with primary antibodies, followed by FITC or rhodamine-linked secondary antibodies. After being washed in PBS thrice, the slides were removed and mounted with Prolong Gold antifade reagent (Molecular Probes), containing 4',6-diamidino-2-phenylindole. The slides were read under a Nikon Eclipse 50i fluorescence microscope or an Olympus IX71 fluorescence microscope using Fluoview version 4.3 software.

Western Blot Analysis

Western blot analysis was done as we have previously described (16). The immunoprecipitation experiments were done as follows: cells were lysed in radioimmunoprecipitation assay buffer [50 mmol/L Tris-HCl (pH 8), 150 mmol/L NaCl, 1% NP40, 0.5% sodium deoxycholate,

⁴ Supplementary material for this article is available at Molecular Cancer Therapeutics Online (<http://mct.aacrjournals.org/>).

and 0.1% SDS], passed through 21-gauge needles 10 times, and centrifuged at 10,000 rpm for 10 min. The supernatant was harvested and incubated with primary antibodies overnight under mild rotation. IgA/G beads (25 μ L) were then added and the mixture was shaken for \sim 1 h. The beads were spun down and washed thrice with cold PBS. The beads were diluted with loading buffer and heated at 95°C for 10 min; SDS-PAGE and Western blot analysis were then performed.

Luciferase Assay

Cells (3×10^4 /well) were seeded in 24-well plates overnight. They were then grown in serum-free medium for 12 h, followed by transfection with 250 ng of different luciferase reporter plasmids. FuGENE 6 (Roche Molecular Biochemicals) was used for plasmid transfection. The cells were kept in normal medium for another 24 h and then treated with 1 μ M oncrasin-1 for different times. Cells were harvested for the luciferase activity assay, which was done using the luciferase assay system (Promega Life Science) as instructed by the manufacturer. Cells transfected with pCDNA3.1 were used as the control.

Kinase Activity Assay

The kinase reactions (20 μ L) were done at 30°C for 15 min. The solution contained 1 \times reaction buffer, 5 mmol/L MgCl₂, 50 μ M cold ATP, 1 μ L γ [P³²]ATP (3,000 Ci/mmol), 50 ng individual kinase, and their corresponding substrates. CDK7/9 tide (500 mmol/L) was used as the substrate for CDK9/cyclin T1, CDK7/cyclin H/MAT1, whereas 0.1 mg/mL histone H1 was used for CDK2/cyclin A and CDK6/cyclin D3 kinase assay. The mix was incubated with different doses of oncrasin-1. Free γ [P³²]ATP was washed away through P81 phosphocellulose filters. The samples were read under a scintillation counter.

In vitro Binding Assay

Recombinant PKC ζ and CDK9/cyclin T1 were mixed *in vitro* with or without 1 μ M oncrasin-1. The mixture

was gently mixed at 4°C for 2 h and then precipitated with anti-PKC ζ antibody. Normal rabbit IgG was used as the antibody control. The CDK9/cyclin T1 complex was used as a positive control for cyclin T1.

Statistical Analysis

Differences between the treatment groups were assessed by ANOVA using statistical software STATISTIC 6.0 (StatSoft). *P* values of <0.05 were considered significant.

Results

Oncrasin-1 Induced Aggregation of SC35, Similar to PKC ζ

We recently found that oncrasin-1 induces apoptosis in the K-Ras-transformed tumorigenic human ovarian T29Kt1 cell line but not in its parental, immortalized normal ovarian epithelial T29 cell line. Characterization of molecular mechanisms by testing on the levels and/or phosphorylation status of several proteins that are involved in apoptosis and/or Ras signaling pathways did not produce elucidative information. The oncrasin-1-induced antitumor activity is not affected by the Raf inhibitor Bay 43-9006, MEK inhibitor U0126, phosphatidylinositol 3-kinase inhibitor LY294002, and AKT inhibitor X (Supplementary Fig. S2).⁴ Nevertheless, oncrasin-1 treatment resulted in the aggregation of PKC ζ into a few large foci inside the nuclei (Fig. 1A). To determine the causes and biological consequences of this abnormal subcellular distribution of PKC ζ , we tested the effect of oncrasin-1 on Rad51, a homologous DNA recombinase involved in DNA repair (17), and on SC35, a protein required for RNA splicing and spliceosome assembly (18). These molecules were selected for testing because they are involved with DNA or RNA metabolisms, the major nuclei events.

In DMSO-treated cells, Rad51 was uniformly distributed inside the nucleus, whereas SC35 was localized in the




Figure 2. Colocalization of PKC ζ and SC35. **A**, fluorescence microscopy examination. **B**, confocal examination. T29Kt1 cells were treated with 10 μ M oncrasin-1 for 12 h and immunofluorescent costaining was done to determine the intracellular localization of PKC ζ and SC35.

444 Interruption of RNA Processing Machinery by Oncrasin-1




Figure 3. Colocalization of PKC ι and ASF/SF2. Fluorescence microscopy examination. T29Kt1 cells were treated with 10 μ mol/L oncrasin-1 for 12 h and immunofluorescent costaining was done to determine the intracellular localization of PKC ι and ASF/SF2.

nucleus as small speckles, either diffusely distributed or concentrated as clusters of granules (19). Oncrasin-1 treatment had no obvious effect on Rad51 but resulted in aggregation of SC35 into several large foci in T29Kt1, a phenomenon similar to that seen in PKC ι . On the other hand, treatment with 10-Gy radiations resulted in the formation of tiny foci of Rad51 in the nucleus, with no noticeable effect on SC35 (Fig. 1B). This result suggests that oncrasin-1 affects RNA processing machinery instead of inducing DNA damage.

PKC ι Colocalized with Splicing Factors

Because oncrasin-1 induced similar nuclear distribution changes in PKC ι and SC35, we determined whether they colocalized in the nucleus after oncrasin-1 treatment. T29Kt1 cells were treated with 10 μ mol/L oncrasin-1 for 12 hours, costained with rabbit anti-PKC ι and mouse anti-SC35 antibodies overnight, and incubated with FITC-labeled goat anti-rabbit immunoglobulin and rhodamine-labeled goat anti-mouse antibodies sequentially. After oncrasin-1 treatment, PKC ι and SC35 were colocalized in megafoci in nuclei, possibly in megaspliceosomes (Fig. 2A). This result was further confirmed on examination of the slides under a confocal Olympus IX71 microscope with Fluoview version 4.3 software (Olympus; Fig. 2B).

We then tested whether oncrasin-1 treatment elicited similar effects on other proteins involved in RNA splicing. After oncrasin-1 treatment, T29Kt1 cells were costained with rabbit anti-PKC ι and mouse anti-ASF/SF2 antibodies overnight and incubated with FITC-labeled goat anti-rabbit IgG and rhodamine-labeled goat anti-mouse antibodies sequentially. Similar to the effect seen in SC35, treatment with oncrasin-1 led to colocalization of PKC ι and ASF/SF2

into megafoci in nuclei (Fig. 3). Together, these results suggest that PKC ι is part of the RNA splicing machinery and aggregated into megaspliceosomes upon the treatment of oncrasin-1 in sensitive cells.

Oncrasin-1 Inhibited RNA Polymerase II and Serine-Arginine-Rich Protein Phosphorylation

Splicing factors are present in mammalian cells in nuclear compartments or speckles. As seen on electron microscopy, speckles consist of two distinct morphologic parts: the larger and more concentrated regions are called interchromatin granule clusters, which are transcriptionally inactive, and the more diffusely distributed splicing factors and regions at the periphery of interchromatin granule clusters correspond to perichromatin fibrils, which contain nascent transcripts (20–22). Speckles are highly dynamic structures that respond specifically to the activation of nearby genes. These dynamic events depend on RNA polymerase II transcription (19, 23). Upon inhibition of RNA polymerase II transcription (24, 25) or pre-mRNA splicing by oligonucleotides or antibodies (26), splicing factors redistribute and preferentially localize to interchromatin granule clusters, which become larger, inactive, and more uniform in shape. This aggregation of splicing factors into large foci suggests that oncrasin-1 affects RNA processing (transcription, splicing, or both). To determine whether oncrasin-1 has a biochemical effect on the proteins involved in RNA transcription or splicing, we evaluated the phosphorylation of the largest subunit of RNA polymerase II and splicing factors after oncrasin-1 treatment. T29, T29Kt1, and H460 cells were treated with oncrasin-1 at an optimal concentration (10 μ mol/L for T29 and T29Kt1 and 1 μ mol/L for H460). Cell lysates were collected 12 hours after treatment and subjected to Western blot analysis with antibodies specific for phosphorylated RNA polymerase II and serine-arginine-rich (SR) proteins. The results showed that oncrasin-1 treatment led to a dramatic suppression of phosphorylated RNA polymerase II and some SR proteins (Fig. 4A), suggesting that oncrasin-1 treatment affects biological functions of RNA processing factors. We also tested the time-dependent suppression of oncrasin-1 on RNA-processing factors in H460 cells. The phosphorylation of RNA polymerase II and SR proteins was reduced starting at 8 hours after oncrasin-1 treatment. This effect was more striking at 12 and 24 hours after treatment (Fig. 4B). Interestingly, oncrasin-1 did not induce obvious suppression of phosphorylated RNA polymerase II in H1299 cells that harbor an N-Ras mutation or in H322 cells that have wild-type Ras genes (Fig. 4C). Both H1299 and H322 cells are resistant to oncrasin-1 treatment.

Oncrasin-1 Inhibited the Transcription of Luciferase Reporter Gene Driven by Different Promoters

The dramatic effect on the phosphorylation status of the largest subunit of RNA polymerase II suggested that oncrasin-1 affects RNA transcription. To investigate this hypothesis, we transfected H460, T29Kt1, and T29 cells with pCMV-Luc plasmid expressing firefly luciferase




Figure 4. Effects of oncrasin-1 on the phosphorylation of RNA polymerase II and SR proteins. **A**, T29, T29Kt1, and H460 cells were treated with DMSO (C) or oncrasin-1 (T) (10 μ mol/L for T29 and T29Kt1 and 1 μ mol/L for H460) for 12 h. Cells were harvested for Western blot analysis with antibodies for the phosphorylated largest subunit of RNA polymerase II [H5 (pPol II)], phosphorylated SR proteins (pSR). Note the reduced levels of phosphorylation of RNA polymerase II and SR proteins. β -Actin was used as the loading control. **B**, time course of the effects of oncrasin-1 on the inhibition of RNA polymerase II and SR protein phosphorylation. H460 cells were treated with DMSO or 1 μ mol/L oncrasin-1 for the indicated times and a Western blot analysis was done. **C**, effects on phosphorylation of CTD in lung cancer cell lines. H322 (with wild-type Ras genes), H1299 (with N-Ras mutation), and 460 (with K-Ras mutation) were treated with DMSO (C) or 1 μ mol/L oncrasin-1 (T) for 12 h and a Western blot analysis was done with H5 pPol II antibody.

driven by cytomegalovirus promoter (Promega) or pRL-TK-Luc plasmid expressing renilla luciferase driven by herpes simplex virus thymidine kinase promoter (Promega); allowed the cells grow for 24 hours; and then treated them with 1 μ mol/L oncrasin-1, DMSO, or 100 μ mol/L of 5,6-dichloro-1-/3-D ribofuranosylbenzimidazole (DRB), which is a known transcription inhibitor (27, 28). Cells were harvested at different times after treatment and luciferase activity was determined. The data were then normalized to corresponding DMSO control groups. Compared with DMSO, oncrasin-1 markedly inhibited the expression of luciferase in H460 and T29Kt1 cells but has no effect or only mild effect in T29 cells (Fig. 5). The transcriptional inhibition effect of oncrasin-1 was stronger than that of DRB. Because the plasmids used in this experiment do not contain introns and do not require splicing for luciferase expression, these results suggest that treatment with oncrasin-1 led to inhibition of RNA transcriptional function.

Oncrasin-1 Induced the Dissociation between PKC ζ and the CDK9/Cyclin T1 Complex

Phosphorylation of the COOH-terminal domain (CTD) of the largest subunit of eukaryotic RNA polymerase II is required for efficient transcription elongation and recruitment of mRNA processing factors, including capping the enzyme and splicing factors required for efficient processing of RNA transcripts (28–31). Polymerase II enters the assembling transcription complex with its CTD unphosphorylated (IIa form). Phosphorylation of CTD by CDK7 and CDK9 converts polymerase II to its phosphorylated form, enabling efficient RNA elongation and processing (29, 30). To determine whether oncrasin-1 has a direct effect on CDK7, CDK9, or other cyclin-dependent kinases, we evaluated the kinase activity of recombinant CDK2, CDK6, CDK7, and CDK9 with or without oncrasin-1. The *in vitro* kinase assay results showed that oncrasin-1 inhibited the kinase activity of CDK6 and CDK9 in a dose-dependent manner (Supplementary Fig. S3).




Figure 5. Oncrasin-1 inhibited transcription of the luciferase reporter gene driven by different promoters. H460, T29, and T29Kt1 were transfected with pCMV-Luc or pRL-TK-Luc plasmids. Twenty-four hours after transfection, cells were treated with oncrasin-1 (10 μ mol/L for T29 and T29Kt1 and 1 μ mol/L for H460), DMSO, or 100 μ mol/L DRB for the indicated time periods. Cells were harvested at 4, 8, and 12 h after treatment and the luciferase activities were determined. The values of DMSO treatment groups served as controls. Their values were set up as 1. The values (relative luciferase activities) of oncrasin-1 and DRB treatment groups were normalized to the corresponding DMSO control groups. Columns, mean of three assays; bars, SD.


446 **Interruption of RNA Processing Machinery by Oncrasin-1**

Figure 6. Effect on PKC ι and cyclin T1 interaction. **A**, immunoprecipitation of PKC ι and the CDK9/cyclin T1 complex. H460 cells were treated with DMSO or 1 μ M oncrasin-1 for 12 h. Cell lysates were harvested to perform the immunoprecipitation (IP) assay. Normal rabbit IgG was used as the control. **B**, recombinant PKC ι and CDK9/cyclin T1 were mixed *in vitro* and then precipitated with anti-PKC ι antibody. Normal rabbit IgG was used as the antibody control. CDK9/cyclin T1 complex was used as a positive control for cyclin T1.

However, at a high concentration, oncrasin-1 also inhibited CDK2 and CDK7. Nevertheless, the direct inhibitory effect of oncrasin-1 on those kinases was moderate and it required high concentrations of oncrasin-1 to suppress 50% of enzymatic activity (Supplementary Fig. S3).⁴ The abnormal distribution of PKC ι led us to perform an immunoprecipitation assay to detect possible interaction between PKC ι and the CDK9/cyclin T1 complex. In DMSO-treated cells, PKC ι can be coprecipitated with cyclin T1-specific antibodies. However, after oncrasin-1 treatment, PKC ι was not detected in the CDK9/cyclin T1 complex (Fig. 6A). The disruption of the interaction between PKC ι and cyclin T1 was also observed in an *in vitro* assay with recombinant PKC ι and CDK9/cyclin T1 complex. PKC ι -specific antibody but not a control antibody could effectively precipitate PKC ι and cyclin T1. However, the presence of oncrasin-1 dramatically suppressed this immunoprecipitation (Fig. 6B). These data indicate that PKC ι is part of the CDK9/cyclin T1 complex in cells and that the interaction between PKC ι and the CDK9/cyclin T1 complex was disrupted by oncrasin-1 treatment, which may lead to transcription dysfunction.

Discussion

Both SC35 and ASF/SF2 proteins are members of the SR protein family, which contains an NH₂-terminal RNA-binding domain that interacts with pre-mRNA and a COOH-terminal SR domain that functions as a protein interaction domain (32). SR proteins are essential for both the operation and regulation of RNA splicing. As part of the large nuclear protein complex called a spliceosome, these proteins are localized in the nucleus as highly dynamic structures known as speckles. The morphologic characteristics of speckles depend on the functions of RNA polymerase II and splicing factors. Under normal conditions, the nucleus of mammalian cells contains 20 to 40 tiny speckles (19). However, when the function of RNA polymerase II or pre-mRNA splicing factors is suppressed, spliceosomes aggregate into a few large foci, known as megaspliceosomes (24–26). The formation of megaspliceosomes is a hallmark of functional disruption of the RNA processing machinery. In this study, we found that oncrasin-1 treatment led to aggregation of both SC35 and

ASF/SF2 into megaspliceosomes, suggesting that one biological effect induced by oncrasin-1 is disruption of the RNA processing machinery.

Because phosphorylation of the CTD domain of the largest subunit of RNA polymerase II is a critical step for both the transcriptional elongation and regulation of pre-mRNA splicing (33), we tested the phosphorylation status of CTD by Western blot analysis. Phosphorylation of the CTD domain and SR proteins were suppressed by oncrasin-1 treatment, suggesting that oncrasin-1 affects RNA elongation, RNA splicing, or both. The expression of intronless reporter genes was significantly suppressed by oncrasin-1, indicating that inhibition of RNA transcription is one of the major biological events induced by this compound. Because inhibition of RNA polymerase II will lead to inhibition of RNA splicing machinery, it is not clear whether malfunction of spliceosomes is an indirect effect of suppression of RNA polymerase II.

Messenger RNA production by RNA polymerase II is the first step in gene expression and is central to the life of cells. Evidence also indicates that transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis (28). Inhibition of polymerase II in untransformed cells resulted in growth arrest but not apoptosis. In contrast, transforming cells with c-Myc dramatically increased their sensitivity to DRB, an adenosine analogue that inhibits CDK7 and CDK9, indicating that apoptosis after the inhibition of RNA polymerase II function is greatly enhanced by oncogenic expression (28). The suppression of CTD phosphorylation by oncrasin-1 led us to evaluate the effects of oncrasin-1 on the kinase activities of recombinant CDK7 and CDK9. Oncrasin-1 had moderate inhibitory effect on the kinase activity of CDK9, CDK6, CDK7, and CDK2. An analysis of cultured cells revealed that oncrasin-1 treatment disrupted the interaction between cyclin T, a major regulatory subunit of CDK9, and PKC ι , whose abnormal nuclear aggregation led us to perform the studies described here (34). The interaction between cyclin T and PKC ι has not been previously reported, although it was reported by others that CDK7 was colocalized with and phosphorylated by PKC ι (35). However, whether PKC ι actively participates in the regulation of CDK7 or CDK9 activity is not yet clear. Although the oncrasin-1-induced abnormal subcellular

distribution of PKC α led us to discover the effects of oncrasin-1 on RNA processing machineries, it needs further investigation to determine possible role of PKC α in regulating RNA transcription and splicing, including the interaction between PKC α and cyclin T1.

It is noteworthy that oncrasin-1 was originally identified through synthetic lethality screening in K-Ras mutant tumor cells. Whether active K-Ras facilitates oncrasin-1-mediated RNA polymerase II suppression is not yet clear. However, Ras proteins are involved in regulation of RNA polymerase II phosphorylation and function (36, 37). Interestingly, mutations compromising the function of CTD were reported to be synthetically lethal with alterations that led to elevated levels of Ras signaling pathway in yeast (38). It is possible that, similar to genetic disruption of CTD function observed in yeast, inhibition of CTD function by oncrasin-1 is synthetically lethal for elevated K-Ras activities. Nevertheless, we could not detect the obvious effect of oncrasin-1 on CTD phosphorylation in normal human ovarian epithelial cells T29 and in human lung cancer cell lines H1299 (with N-Ras mutation) and H322 (with wild-type Ras genes). Thus, it is also possible that K-Ras and oncrasin-interacting protein both regulate CTD phosphorylation. Functional change of either alone, such as elevated K-Ras activity or alteration of oncrasin-interacting protein, is not sufficient to alter CTD phosphorylation. However, if they occur together, the combination leads to CTD dephosphorylation and, as a result, the death of the cell.

Disclosure of Potential Conflicts of Interest

M.D. Anderson filed a patent for oncrasin-1; W. Guo, S. Wu, J. Liu, and B. Fang are the inventors. No other potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Jack A. Roth for helpful suggestions, Ann Sutton for editorial review of the manuscript, and Henry Peng and Jennifer Wang for technical assistance.

References

- Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. *Science* 1992;258:607–14.
- Fedorov YV, Jones NC, Olwin BB. Atypical protein kinase Cs are the Ras effectors that mediate repression of myogenic satellite cell differentiation. *Mol Cell Biol* 2002;22:1140–9.
- Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isoforms controlled by phosphoinositide 3-kinase through the protein kinase PDK1. *Science* 1998;281:2042–5.
- Cornford P, Evans J, Dodson A, et al. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. *Am J Pathol* 1999;154:137–44.
- Eder AM, Sui X, Rosen DG, et al. Atypical PKC α contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. *Proc Natl Acad Sci U S A* 2005;102:12519–24.
- Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase C α is an oncogene in human non-small cell lung cancer. *Cancer Res* 2005;65:8905–11.
- Murray NR, Jamieson L, Yu W, et al. Protein kinase C α is required for Ras transformation and colon carcinogenesis *in vivo*. *J Cell Biol* 2004;164:797–802.
- Terasawa H, Noda Y, Ito T, et al. Structure and ligand recognition of the PB1 domain: a novel protein module binding to the PC motif. *EMBO J* 2001;20:3947–56.
- Diaz-Meco MT, Moscat J. MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signaling. *Mol Cell Biol* 2001;21:1218–27.
- Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD, Pawson T. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. *Nat Cell Biol* 2000;2:540–7.
- Puls A, Schmidt S, Grawe F, Stabel S. Interaction of protein kinase C α with ZIP, a novel protein kinase C-binding protein. *Proc Natl Acad Sci U S A* 1997;94:6191–6.
- Zhou G, Seibenhener ML, Wooten MW. Nucleolin is a protein kinase C α substrate. Connection between cell surface signaling and nucleus in PC12 cells. *J Biol Chem* 1997;272:31130–7.
- Leitges M, Sanz L, Martin P, et al. Targeted disruption of the ζ PKC gene results in the impairment of the NF- κ B pathway. *Mol Cell* 2001;8:771–80.
- Soloff RS, Katayama C, Lin MY, Feramisco JR, Hedrick SM. Targeted deletion of protein kinase C λ reveals a distribution of functions between the two atypical protein kinase C isoforms. *J Immunol* 2004;173:3250–60.
- Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C α . *Cancer Res* 2008;68:7403–8.
- Teraishi F, Wu S, Sasaki J, et al. JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells. *Cell Mol Life Sci* 2005;62:2382–9.
- Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions *in vitro*. *Cell* 1996;87:757–66.
- Fu XD, Maniatis T. Isolation of a complementary DNA that encodes the mammalian splicing factor SC35. *Science* 1992;256:535–8.
- Misteli T, Caceres JF, Spector DL. The dynamics of a pre-mRNA splicing factor in living cells. *Nature* 1997;387:523–7.
- Fakan S, Bernhard W. Localisation of rapidly and slowly labelled nuclear RNA as visualized by high resolution autoradiography. *Exp Cell Res* 1971;67:129–41.
- Fakan S, Nobis P. Ultrastructural localization of transcription sites and of RNA distribution during the cell cycle of synchronized CHO cells. *Exp Cell Res* 1978;113:327–37.
- Spector DL. Macromolecular domains within the cell nucleus. *Annu Rev Cell Biol* 1993;9:265–315.
- Spector DL. Nuclear organization and gene expression. *Exp Cell Res* 1996;229:189–97.
- Carmo-Fonseca M, Pepperkok R, Carvalho MT, Lamond AI. Transcription-dependent colocalization of the U1, U2, U4/U6, and U5 snRNPs in coiled bodies. *J Cell Biol* 1992;117:1–14.
- Zeng C, Kim E, Warren SL, Berget SM. Dynamic relocation of transcription and splicing factors dependent upon transcriptional activity. *EMBO J* 1997;16:1401–12.
- O'Keefe RT, Mayeda A, Sadowski CL, Krainer AR, Spector DL. Disruption of pre-mRNA splicing *in vivo* results in reorganization of splicing factors. *J Cell Biol* 1994;124:249–60.
- Blaydes JP, Craig AL, Wallace M, et al. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. *Oncogene* 2000;19:3829–39.
- Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. *Mol Cell Biol* 1997;17:7306–16.
- McCracken S, Fong N, Yankulov K, et al. The C-terminal domain of RNA polymerase II couples mRNA processing to transcription. *Nature* 1997;385:357–61.
- Misteli T, Spector DL. RNA polymerase II targets pre-mRNA splicing factors to transcription sites *in vivo*. *Mol Cell* 1999;3:697–705.
- Mortillaro MJ, Blencowe BJ, Wei X, et al. A hyperphosphorylated form of the large subunit of RNA polymerase II is associated with splicing complexes and the nuclear matrix. *Proc Natl Acad Sci U S A* 1996;93:8253–57.
- Graveley BR. Sorting out the complexity of SR protein functions. *RNA* 2000;6:1197–211.

448 Interruption of RNA Processing Machinery by Oncrasin-1

33. Hirose Y, Tacke R, Manley JL. Phosphorylated RNA polymerase II stimulates pre-mRNA splicing. *Genes Dev* 1999;13:1234–9.
34. Acevedo-Duncan M, Patel R, Whelan S, Bicaku E. Human glioma PKC- ι and PKC- β II phosphorylate cyclin-dependent kinase activating kinase during the cell cycle. *Cell Prolif* 2002;35:23–36.
35. Bicaku E, Patel R, Acevedo-Duncan M. Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC- ι in human glioma cells. *Tissue Cell* 2005;37:53–8.
36. Abdellatif M, Packer SE, Michael LH, Zhang D, Charng MJ, Schneider MD. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy. *Mol Cell Biol* 1998;18:6729–36.
37. Chang YW, Howard SC, Herman PK. The Ras/PKA signaling pathway directly targets the Srb9 protein, a component of the general RNA polymerase II transcription apparatus. *Mol Cell* 2004;15:107–16.
38. Howard SC, Budovskaya YV, Chang YW, Herman PK. The C-terminal domain of the largest subunit of RNA polymerase II is required for stationary phase entry and functionally interacts with the Ras/PKA signaling pathway. *J Biol Chem* 2002;277:19488–97.

Molecular Cancer Therapeutics

Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1 *H*-indole-3-carboxaldehyde (oncrasin-1)

Wei Guo, Shuhong Wu, Li Wang, et al.

Mol Cancer Ther 2009;8:441-448. Published OnlineFirst February 10, 2009.

Updated version	Access the most recent version of this article at: doi: 10.1158/1535-7163.MCT-08-0839
Supplementary Material	Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2009/02/02/1535-7163.MCT-08-0839.DC1

Cited articles	This article cites 38 articles, 21 of which you can access for free at: http://mct.aacrjournals.org/content/8/2/441.full#ref-list-1
Citing articles	This article has been cited by 1 HighWire-hosted articles. Access the articles at: http://mct.aacrjournals.org/content/8/2/441.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/8/2/441 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.